---
title: "Humira (adalimumab), all indications: Safety questions"
description: "Safety questions on Humira (adalimumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Vaccines, Side effects, and Safety evidence. Questions: Does Humira have a boxed warning for serious infections and cancer? Does Humira increase the risk of serious infections? Can Humira cause tuberculosis (TB)? Can Humira cause fungal infections such as histoplasmosis? 13 further questions follow. 17 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/humira/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Humira (adalimumab), all indications: Safety questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Humira](https://www.rxabbvie.com/pdf/humira.pdf)  
Indication pages: [Rheumatoid arthritis](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis)

## Warnings

<a id="humira-boxed-warning"></a>

### Does Humira have a boxed warning for serious infections and cancer?

> “WARNING: SERIOUS INFECTIONS AND MALIGNANCY 
> SERIOUS INFECTIONS 
> Patients treated with HUMIRA are at increased risk for developing serious infections 
> that may lead to hospitalization or death [see Warnings and Precautions (5.1)]. Most 
> patients who developed these infections were taking concomitant immunosuppressants 
> such as methotrexate or corticosteroids. 
> Discontinue HUMIRA if a patient develops a serious infection or sepsis. 
> Reported infections include: 
> • Active tuberculosis (TB), including reactivation of latent TB. Patients with TB 
> have frequently presented with disseminated or extrapulmonary disease. Test 
> patients for latent TB before HUMIRA use and during therapy. Initiate 
> treatment for latent TB prior to HUMIRA use. 
> • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, 
> candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with 
> histoplasmosis or other invasive fungal infections may present with disseminated, 
> rather than localized, disease. Antigen and antibody testing for histoplasmosis 
> may be negative in some patients with active infection. Consider empiric anti-
> fungal therapy in patients at risk for invasive fungal infections who develop 
> severe systemic illness. 
> • Bacterial, viral and other infections due to opportunistic pathogens, including 
> Legionella and Listeria. 
>
> Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating 
> therapy in patients with chronic or recurrent infection. 
> Monitor patients closely for the development of signs and symptoms of infection during 
> and after treatment with HUMIRA, including the possible development of TB in 
> patients who tested negative for latent TB infection prior to initiating therapy [see 
> Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. 
> MALIGNANCY 
> Lymphoma and other malignancies, some fatal, have been reported in children and 
> adolescent patients treated with TNF blockers including HUMIRA [see Warnings and 
> Precautions (5.2)]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a 
> rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers 
> including HUMIRA. These cases have had a very aggressive disease course and have 
> been fatal. The majority of reported TNF blocker cases have occurred in patients with 
> Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult 
> males. Almost all these patients had received treatment with azathioprine or 6-
> mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is 
> uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF”

Source: [HUMIRA: Prescribing information, page 3, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=3)

> “blocker in combination with these other immunosuppressants [see Warnings and 
> Precautions (5.2)].”

Source: [HUMIRA: Prescribing information, page 4, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=4)

Note: The two passages are the boxed warning of the full Prescribing Information, which continues from page 3 to page 4.

<a id="humira-serious-infections"></a>

### Does Humira increase the risk of serious infections?

> “Treatment with HUMIRA should not be initiated in patients with an active infection, including 
> localized infections. Patients 65 years of age and older, patients with co-morbid conditions 
> and/or patients taking concomitant immunosuppressants (such as corticosteroids or 
> methotrexate), may be at greater risk of infection. Consider the risks and benefits of treatment 
> prior to initiating therapy in patients:  
> • with chronic or recurrent infection; 
> • who have been exposed to tuberculosis; 
> • with a history of an opportunistic infection; 
> • who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as 
> histoplasmosis, coccidioidomycosis, or blastomycosis; or  
> • with underlying conditions that may predispose them to infection.”

Source: [HUMIRA: Prescribing information, page 9, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=9)

> “In the controlled portions of the 39 global HUMIRA clinical trials in adult subjects with RA, 
> PsA, AS, CD, UC, Ps, HS and UV, the rate of serious infections was 4.3 per 100 patient-years in 
> 7973 HUMIRA-treated subjects versus a rate of 2.9 per 100 patient-years in 4848 control-treated 
> subjects. Serious infections observed included pneumonia, septic arthritis, prosthetic and post-”

Source: [HUMIRA: Prescribing information, page 14, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=14)

> “surgical infections, erysipelas, cellulitis, diverticulitis, and pyelonephritis”

Source: [HUMIRA: Prescribing information, page 15, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=15)

> “Discontinue HUMIRA if a patient develops a serious infection or sepsis. For a patient who 
> develops a new infection during treatment with HUMIRA, closely monitor them, perform a 
> prompt and complete diagnostic workup appropriate for an immunocompromised patient, and 
> initiate appropriate antimicrobial therapy.”

Source: [HUMIRA: Prescribing information, page 10, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=10)

Note: The second passage ends mid-sentence at the foot of page 14 of the Prescribing Information; the third passage completes the sentence on page 15.

<a id="humira-tuberculosis"></a>

### Can Humira cause tuberculosis (TB)?

> “Cases of reactivation of tuberculosis and new onset tuberculosis infections have been reported in 
> patients receiving HUMIRA, including patients who have previously received treatment for 
> latent or active tuberculosis. Reports included cases of pulmonary and extrapulmonary (i.e., 
> disseminated) tuberculosis. Evaluate patients for tuberculosis risk factors and test for latent 
> infection prior to initiating HUMIRA and periodically during therapy.”

Source: [HUMIRA: Prescribing information, page 9, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=9)

> “In 52 global controlled and uncontrolled clinical trials in RA, PsA, AS, CD, UC, Ps, HS and UV 
> that included 24,605 HUMIRA-treated subjects, the rate of reported active tuberculosis was 0.20 
> per 100 patient-years and the rate of positive PPD conversion was 0.09 per 100 patient-years. In 
> a subgroup of 10,113 U.S. and Canadian HUMIRA-treated subjects, the rate of reported active 
> TB was 0.05 per 100 patient-years and the rate of positive PPD conversion was 0.07 per 100 
> patient-years. These trials included reports of miliary, lymphatic, peritoneal, and pulmonary TB. 
> Most of the TB cases occurred within the first eight months after initiation of therapy and may 
> reflect recrudescence of latent disease. In these global clinical trials, cases of serious 
> opportunistic infections have been reported at an overall rate of 0.05 per 100 patient-years. Some 
> cases of serious opportunistic infections and TB have been fatal [see Warnings and Precautions 
> (5.1)].”

Source: [HUMIRA: Prescribing information, page 15, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=15)

<a id="humira-fungal-infections"></a>

### Can Humira cause fungal infections such as histoplasmosis?

> “• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, 
> candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with 
> histoplasmosis or other invasive fungal infections may present with disseminated, 
> rather than localized, disease. Antigen and antibody testing for histoplasmosis 
> may be negative in some patients with active infection. Consider empiric anti-
> fungal therapy in patients at risk for invasive fungal infections who develop 
> severe systemic illness.”

Source: [HUMIRA: Prescribing information, page 3, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=3)

> “Invasive Fungal Infections 
> If patients develop a serious systemic illness and they reside or travel in regions where mycoses 
> are endemic, consider invasive fungal infection in the differential diagnosis. Antigen and 
> antibody testing for histoplasmosis may be negative in some patients with active infection. 
> Consider appropriate empiric antifungal therapy, taking into account both the risk for severe 
> fungal infection and the risks of antifungal therapy, while a diagnostic workup is being 
> performed. To aid in the management of such patients, consider consultation with a physician 
> with expertise in the diagnosis and treatment of invasive fungal infections.”

Source: [HUMIRA: Prescribing information, page 10, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=10)

<a id="humira-cancer-risk"></a>

### Does Humira increase the risk of cancer?

> “In the controlled portions of clinical trials of some TNF-blockers, including HUMIRA, more 
> cases of malignancies have been observed among TNF-blocker-treated adult subjects compared 
> to control-treated adult subjects. During the controlled portions of 39 global HUMIRA clinical 
> trials in adult subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing 
> spondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), plaque psoriasis (Ps), 
> hidradenitis suppurativa (HS) and uveitis (UV), malignancies, other than non-melanoma (basal 
> cell and squamous cell) skin cancer, were observed at a rate (95% confidence interval) of 0.7 
> (0.48, 1.03) per 100 patient-years among 7973 HUMIRA-treated subjects versus a rate of 0.7 
> (0.41, 1.17) per 100 patient-years among 4848 control-treated subjects (median duration of 
> treatment of 4 months for HUMIRA-treated subjects and 4 months for control-treated subjects). 
> In 52 global controlled and uncontrolled clinical trials of HUMIRA in adult subjects with RA, 
> PsA, AS, CD, UC, Ps, HS and UV, the most frequently observed malignancies, other than 
> lymphoma and NMSC, were breast, colon, prostate, lung, and melanoma. The malignancies in 
> HUMIRA-treated subjects in the controlled and uncontrolled portions of the studies were similar 
> in type and number to what would be expected in the general U.S. population according to the 
> SEER database (adjusted for age, gender, and race).<sup>1</sup>”

Source: [HUMIRA: Prescribing information, page 10, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=10)

> “Consider the risks and benefits of TNF-blocker treatment including HUMIRA prior to initiating 
> therapy in patients with a known malignancy other than a successfully treated non-melanoma 
> skin cancer (NMSC) or when considering continuing a TNF blocker in patients who develop a 
> malignancy.”

Source: [HUMIRA: Prescribing information, page 10, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=10)

<a id="humira-lymphoma-risk"></a>

### Does Humira increase the risk of lymphoma or leukemia?

> “In the controlled portions of clinical trials of all the TNF-blockers in adults, more cases of 
> lymphoma have been observed among TNF-blocker-treated subjects compared to control-treated 
> subjects. In the controlled portions of 39 global HUMIRA clinical trials in adult subjects with 
> RA, PsA, AS, CD, UC, Ps, HS and UV, 2 lymphomas occurred among 7973 HUMIRA-treated 
> subjects versus 1 among 4848 control-treated subjects. In 52 global controlled and uncontrolled 
> clinical trials of HUMIRA in adult subjects with RA, PsA, AS, CD, UC, Ps, HS and UV with a 
> median duration of approximately 0.7 years, including 24,605 subjects and over 40,215 patient-
> years of HUMIRA, the observed rate of lymphomas was approximately 0.11 per 100 patient-
> years. This is approximately 3-fold higher than expected in the general U.S. population 
> according to the SEER database (adjusted for age, gender, and race).<sup>1</sup> Rates of lymphoma in 
> clinical trials of HUMIRA cannot be compared to rates of lymphoma in clinical trials of other 
> TNF blockers and may not predict the rates observed in a broader patient population. Patients 
> with RA and other chronic inflammatory diseases, particularly those with highly active disease 
> and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several 
> fold) than the general population for the development of lymphoma, even in the absence of TNF 
> blockers. Post-marketing cases of acute and chronic leukemia have been reported in association 
> with TNF-blocker use in RA and other indications. Even in the absence of TNF-blocker therapy, 
> patients with RA may be at a higher risk (approximately 2-fold) than the general population for 
> the development of leukemia.”

Source: [HUMIRA: Prescribing information, page 11, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=11)

<a id="humira-skin-cancer"></a>

### Does Humira increase the risk of skin cancer?

> “During the controlled portions of 39 global HUMIRA clinical trials in adult subjects with RA, 
> PsA, AS, CD, UC, Ps, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, 
> 1.09) per 100 patient-years among HUMIRA-treated subjects and 0.2 (0.10, 0.59) per 100 
> patient-years among control-treated subjects. Examine all patients, and in particular patients with 
> a medical history of prior prolonged immunosuppressant therapy or psoriasis patients with a 
> history of PUVA treatment for the presence of NMSC prior to and during treatment with 
> HUMIRA.”

Source: [HUMIRA: Prescribing information, page 11, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=11)

<a id="humira-allergic-reactions"></a>

### Can Humira cause allergic reactions or anaphylaxis?

> “Anaphylaxis and angioneurotic edema have been reported following HUMIRA administration. If 
> an anaphylactic or other serious allergic reaction occurs, immediately discontinue administration 
> of HUMIRA and institute appropriate therapy. In clinical trials of HUMIRA, hypersensitivity 
> reactions (e.g., rash, anaphylactoid reaction, fixed drug reaction, non-specified drug reaction, 
> urticaria) have been observed.”

Source: [HUMIRA: Prescribing information, page 12, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=12)

<a id="humira-hepatitis-b"></a>

### Can Humira reactivate hepatitis B?

> “Use of TNF blockers, including HUMIRA, may increase the risk of reactivation of hepatitis B 
> virus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV 
> reactivation occurring in conjunction with TNF blocker therapy has been fatal. The majority of 
> these reports have occurred in patients concomitantly receiving other medications that suppress 
> the immune system, which may also contribute to HBV reactivation. Evaluate patients at risk for 
> HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy. 
> Exercise caution in prescribing TNF blockers for patients identified as carriers of HBV. 
> Adequate data are not available on the safety or efficacy of treating patients who are carriers of 
> HBV with anti-viral therapy in conjunction with TNF blocker therapy to prevent HBV 
> reactivation. For patients who are carriers of HBV and require treatment with TNF blockers, 
> closely monitor such patients for clinical and laboratory signs of active HBV infection 
> throughout therapy and for several months following termination of therapy. In patients who 
> develop HBV reactivation, stop HUMIRA and initiate effective anti-viral therapy with 
> appropriate supportive treatment. The safety of resuming TNF blocker therapy after HBV 
> reactivation is controlled is not known. Therefore, exercise caution when considering resumption 
> of HUMIRA therapy in this situation and monitor patients closely.”

Source: [HUMIRA: Prescribing information, page 12, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=12)

<a id="humira-demyelinating-disease"></a>

### Can Humira cause multiple sclerosis or other demyelinating disease?

> “Use of TNF blocking agents, including HUMIRA, has been associated with rare cases of new 
> onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous 
> system demyelinating disease, including multiple sclerosis (MS) and optic neuritis, and 
> peripheral demyelinating disease, including Guillain-Barré syndrome. Exercise caution in 
> considering the use of HUMIRA in patients with preexisting or recent-onset central or peripheral 
> nervous system demyelinating disorders; discontinuation of HUMIRA should be considered if 
> any of these disorders develop.”

Source: [HUMIRA: Prescribing information, page 12, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=12)

<a id="humira-blood-disorders"></a>

### Can Humira cause low blood counts?

> “Rare reports of pancytopenia including aplastic anemia have been reported with TNF blocking 
> agents. Adverse reactions of the hematologic system, including medically significant cytopenia 
> (e.g., thrombocytopenia, leukopenia) have been infrequently reported with HUMIRA. The causal 
> relationship of these reports to HUMIRA remains unclear. Advise all patients to seek immediate 
> medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection 
> (e.g., persistent fever, bruising, bleeding, pallor) while on HUMIRA. Consider discontinuation of 
> HUMIRA therapy in patients with confirmed significant hematologic abnormalities.”

Source: [HUMIRA: Prescribing information, page 13, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=13)

<a id="humira-heart-failure"></a>

### Can Humira cause or worsen heart failure?

> “Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with 
> TNF blockers. Cases of worsening CHF have also been observed with HUMIRA. HUMIRA has 
> not been formally studied in patients with CHF; however, in clinical trials of another TNF 
> blocker, a higher rate of serious CHF-related adverse reactions was observed. Exercise caution 
> when using HUMIRA in patients who have heart failure and monitor them carefully.”

Source: [HUMIRA: Prescribing information, page 13, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=13)

<a id="humira-liver"></a>

### Can Humira cause liver problems?

> “There have been reports of severe hepatic reactions including acute liver failure in subjects 
> receiving TNF-blockers. In controlled Phase 3 trials of HUMIRA (40 mg SC every other week) 
> in subjects with RA, PsA, and AS with control period duration ranging from 4 to 104 weeks, 
> ALT elevations ≥ 3 x ULN occurred in 3.5% of HUMIRA-treated subjects and 1.5% of control-
> treated subjects. Since many of these subjects in these trials were also taking medications that 
> cause liver enzyme elevations (e.g., NSAIDS, MTX), the relationship between HUMIRA and the 
> liver enzyme elevations is not clear.”

Source: [HUMIRA: Prescribing information, page 15, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=15)

> “Hepato-biliary disorders: Liver failure, hepatitis, autoimmune hepatitis”

Source: [HUMIRA: Prescribing information, page 22, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=22)

Note: The second passage is from the Postmarketing Experience section, which lists reactions reported voluntarily during post-approval use.

<a id="humira-contraindications"></a>

### What are the contraindications for Humira?

> “4 CONTRAINDICATIONS 
> None.”

Source: [HUMIRA: Prescribing information, page 8, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=8)

## Vaccines

<a id="humira-vaccines"></a>

### Can patients on Humira get vaccines?

> “In a placebo-controlled clinical trial of subjects with RA, no difference was detected in anti-
> pneumococcal antibody response between HUMIRA and placebo treatment groups when the 
> pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently 
> with HUMIRA. Similar proportions of subjects developed protective levels of anti-influenza 
> antibodies between HUMIRA and placebo treatment groups; however, titers in aggregate to 
> influenza antigens were moderately lower in subjects receiving HUMIRA. The clinical 
> significance of this is unknown. Patients on HUMIRA may receive concurrent vaccinations, 
> except for live vaccines. No data are available on the secondary transmission of infection by live 
> vaccines in patients receiving HUMIRA.”

Source: [HUMIRA: Prescribing information, page 13, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=13)

> “Avoid the use of live vaccines with HUMIRA [see Warnings and Precautions (5.10)].”

Source: [HUMIRA: Prescribing information, page 23, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=23)

## Side effects

<a id="humira-injection-site-reactions"></a>

### How common are Humira injection site reactions?

> “The most common adverse reaction with HUMIRA was injection site reactions. In placebo-
> controlled trials, 20% of subjects treated with HUMIRA developed injection site reactions 
> (erythema and/or itching, hemorrhage, pain or swelling), compared to 14% of subjects receiving 
> placebo. Most injection site reactions were described as mild and generally did not necessitate 
> drug discontinuation.”

Source: [HUMIRA: Prescribing information, page 14, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=14)

## Safety evidence

<a id="humira-long-term-safety"></a>

### What are Humira's long-term serious side effects across adult indications, including RA?

> “Evaluated long-term safety data from HUMIRA global clinical trials, including randomized controlled, open-label, and long-term extension studies, assessing serious adverse events (SAEs) of interest. Study was conducted through December 31, 2016.<sup>2*</sup>”

Source: [HUMIRA: HUMIRA® (adalimumab) Safety profile, captured 2026-11-13](https://www.humirapro.com/global-safety#:~:text=Evaluated,was%20conducted%20through%20December%2031%2C)

> “SAEs of interest across 8 adult indications<sup>2,†</sup>
>
> Rates displayed as events per 100 PYs
>
>  	Rheumatoid arthritis
> (RA)
> 37,106 PYs
> N=15,512	Ankylosing spondylitis
> (AS)
> 2,120 PYs
> N=2,026	Psoriatic arthritis
> (PsA)
> 998 PYs
> N=837	Plaque psoriasis
> (Ps)
> 5,479 PYs
> N=3,732	Hidradenitis suppurativa
> (HS)
> 1,198 PYs
> N=733	Crohn’s disease
> (CD)
> 4,359 PYs
> N=3,896	Ulcerative colitis
> (UC)
> 3,407 PYs
> N=1,739	Uveitis
> (UV)<sup>a</sup>
> 1,151 PYs
> N=464
> Serious infection	3.9	1.8	2.8	1.8	2.8	6.9	3.5	4.1
> Tuberculosis	0.2	0.1	0.2	0.2	0	0.2	<0.1	0.4
> Active	0.2	0.1	0.2	0.2	0	0.1	<0.1	0.2
> Latent	<0.1	0	0	0	0	<0.1	0	0.3
> Opportunistic infection<sup>b</sup>	<0.1	0	0	0	0	<0.1	<0.1	0.4
> Demyelinating disorder	<0.1	<0.1	0	0	0	0.1	<0.1	0.3
> Lupus-like syndrome	<0.1	<0.1	0	0	0	<0.1	<0.1	<0.1
> Congestive heart failure	0.2	<0.1	0	0.1	0.2	0	<0.1	<0.1
> Ps new onset/worsening	<0.1	<0.1	0.1	<0.1	<0.1	<0.1	<0.1	0
> Malignancy<sup>c</sup>	0.7	0.2	0.2	0.5	0.5	0.4	0.6	0.7
> Lymphoma	0.1	<0.1	0.2	<0.1	<0.1	<0.1	<0.1	<0.1
> NMSC	0.2	0.2	0.1	0.1	<0.1	<0.1	<0.1	0.2
> Melanoma	<0.1	<0.1	0	0.2	0	0	<0.1	0
> Sarcoidosis	<0.1	<0.1	0	0	0	0	0	<0.1
> Any AE leading to death	0.6	<0.1	0.3	0.2	0.5	0.1	0.1	0.6”

Source: [HUMIRA: HUMIRA® (adalimumab) Safety profile, captured 2026-11-13](https://www.humirapro.com/global-safety#:~:text=SAEs%20of%20interest%20across%208,0.6)

> “Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in a broader patient population in clinical practice.”

Source: [HUMIRA: HUMIRA® (adalimumab) Safety profile, captured 2026-11-13](https://www.humirapro.com/global-safety#:~:text=Because%20clinical%20trials%20are%20conducted,patient%20population%20in%20clinical%20practice.)

> “<sup>a</sup>Non-infectious (NI) intermediate, posterior, and panuveitis.
> <sup>b</sup>Excludes oral candidiasis and tuberculosis.
> <sup>c</sup>Excludes lymphoma, hepatosplenic T-cell lymphoma, leukemia, NMSC, and melanoma.
> *33 in RA, 5 in AS, 3 in PsA, 13 in Ps, 3 in HS, 11 in CD, 4 in UC, and 2 in Non-infectious (NI) intermediate, posterior, or panuveitis.
> <sup>†</sup>Data derived from global clinical trials of HUMIRA, including randomized controlled, open-label, and long-term extension studies (33 in RA, 5 in AS, 3 in PsA, 13 in Ps, 3 in HS, 11 in CD, 4 in UC, and 2 in UV).<sup>2</sup>”

Source: [HUMIRA: HUMIRA® (adalimumab) Safety profile, captured 2026-11-13](https://www.humirapro.com/global-safety#:~:text=%28NI%29%20intermediate%2C%20posterior%2C%20and%20panuveitis.,HS%2C%2011%20in%20CD%2C%204%20in%20UC%2C%20and%202%20in)

Note: The first value column of the table is rheumatoid arthritis (37,106 patient-years, N=15,512); rates are events per 100 patient-years. The page cites Burmester GR, et al. Adv Ther. 2020;37(1):364-380.

## Related pages
- [Medical information: Humira (adalimumab): All indications](https://www.evicenter.com/medical-information/humira)
- [Indication](https://www.evicenter.com/medical-information/humira/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/humira/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/humira/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/humira/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/humira/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/humira/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/humira/access-and-coverage)
